Literature DB >> 27080836

Causality assessment in pharmacovigilance: The French method and its successive updates.

Ghada Miremont-Salamé1, Hélène Théophile2, Françoise Haramburu3, Bernard Bégaud4.   

Abstract

The methods for causality assessment of adverse drug reactions were developed in the 1970s and 1980s, alongside the development of pharmacovigilance. The French method is one of the earlier of these, following on from the pioneering works by Irey and Karch and Lasagna. Initially published in 1978, it was updated in 1985, and again in 2011. The main alterations to the original method are presented in tables annexed to this paper. The successive versions improved the presentation, provided more formalised definitions of the criteria for assessing causality, while at the same time ensuring the method remained easy to use. Causality assessment enables the causal link between a drug and the occurrence of an adverse reaction to be formalised and explained. It contributes to diagnosis, and to determining the action to be taken in case of an adverse drug reaction. It can contribute to the quality and the relevance of the data stored in pharmacovigilance databases.
Copyright © 2016 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Causality assessment; Drug-related side effects and adverse reactions; Imputability; Pharmacovigilance; Risk assessment/methods

Mesh:

Year:  2016        PMID: 27080836     DOI: 10.1016/j.therap.2016.02.010

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  22 in total

1.  A comparative study of QT prolongation with serotonin reuptake inhibitors.

Authors:  Ana Ojero-Senard; Justine Benevent; Emmanuelle Bondon-Guitton; Geneviève Durrieu; Leila Chebane; Melanie Araujo; Francois Montastruc; Jean-Louis Montastruc
Journal:  Psychopharmacology (Berl)       Date:  2017-08-03       Impact factor: 4.530

2.  Serious adverse drug events related to non-investigational drugs in academic clinical trials: another source of safety data for risk assessment?

Authors:  Pascale Olivier; Anne Gimbert; Anne-Laurène Colin; Francesco Salvo; Madlyne Becker; Valérie Marty; Jean-Louis Montastruc; Nadine Petitpain
Journal:  Br J Clin Pharmacol       Date:  2016-07-13       Impact factor: 4.335

Review 3.  Duloxetine and gingival bleeding: a case-report and reviews of the French and World PharmacoVigilance Databases and literature.

Authors:  Céline Gicquel; Florence Moulis; Chouki Chenaf; Aurore Gouraud; Milou Drici; Emmanuelle Bondon-Guitton; François Montastruc; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2017-06-22       Impact factor: 2.953

4.  Vomiting and constipation associated with tramadol and codeine: a comparative study in VigiBase®.

Authors:  François Montastruc; Justine Benevent; Leila Chebane; Vanessa Rousseau; Geneviève Durrieu; Agnès Sommet; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2018-08-10       Impact factor: 2.953

5.  Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases.

Authors:  Quentin Dardonville; Esther Salguiero; Vanessa Rousseau; Leila Chebane; Jean Luc Faillie; Sophie Gautier; Jean Louis Montastruc; Alfonso Carvajal; Haleh Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2019-08-29       Impact factor: 2.953

6.  Comment on "Patient Reporting in the EU: Analysis of EudraVigilance Data".

Authors:  Farid Kheloufi; Anne Default; Frank Rouby; Olivier Blin; Joelle Micallef
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

7.  Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting.

Authors:  François Montastruc; Haleh Bagheri; Isabelle Lacroix; Christine Damase-Michel; Leila Chebane; Vanessa Rousseau; Emilie Jouanjus; Maryse Lapeyre-Mestre; Geneviève Durrieu; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

8.  Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey.

Authors:  Florence Moulis; Vanessa Rousseau; Leila Chebane; Amandine Gouverneur; Louise Gaboriau; Jean-Luc Faillie; Geneviève Durrieu; François Montastruc; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2018-04-14       Impact factor: 2.953

9.  Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.

Authors:  François Montastruc; Florence Moulis; Mélanie Araujo; Leila Chebane; Olivier Rascol; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2016-10-27       Impact factor: 2.953

10.  Adverse Drug Reactions Involving Protein Kinase Inhibitors: A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥ 75 years) with Cancer.

Authors:  Vincent Clapes; Vanessa Rousseau; Fabien Despas; Jean-Louis Montastruc; Pascale Olivier
Journal:  Pharmaceut Med       Date:  2019-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.